This clinical trial is focused on studying a group of rare conditions known as GNAO1 associated disorders. These disorders are linked to changes in the GNAO1 gene and can lead to symptoms such as movement problems, muscle weakness, seizures, and developmental delays. The trial will explore the use of a treatment called Wilzin, which contains the active ingredient zinc acetate dihydrate. Wilzin is available in two forms: 25 mg and 50 mg hard capsules. The purpose of the study is to assess how feasible and safe it is to use oral zinc as a treatment for individuals with GNAO1 associated disorders.

Participants in the study will take the zinc capsules by mouth, and the treatment period will last for several months. Throughout the study, researchers will monitor how often the zinc is taken correctly and will check for any side effects. The study will also look at changes in motor skills, quality of life, and other symptoms related to GNAO1 disorders. Caregivers will help by keeping a daily log of the participant’s behavior, sleep patterns, and any seizures. Blood tests will be conducted to measure zinc levels and to ensure there are no deficiencies in other important substances like ferritin and copper.

The study will also involve analyzing stool samples to see if there are any changes in the gut related to the GNAO1 disorders. Researchers will compare the results to see if different genetic variants of GNAO1 affect the outcomes. The trial aims to provide valuable information on whether zinc can be a safe and effective treatment option for those affected by these rare genetic disorders.